COSCIENS Biopharma Inc.
CSCI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $11 | $9 | $8 | $12 |
| - Cash | $9 | $14 | $16 | $20 |
| + Debt | $2 | $2 | $2 | $2 |
| Enterprise Value | $4 | -$3 | -$6 | -$7 |
| Revenue | $3 | $1 | $3 | $2 |
| % Growth | 83.8% | -55% | 77.6% | – |
| Gross Profit | $1 | $0 | $2 | $1 |
| % Margin | 35.4% | 29.5% | 61.7% | 44.7% |
| EBITDA | -$2 | -$3 | -$5 | -$5 |
| % Margin | -86.9% | -217.3% | -157.6% | -286.8% |
| Net Income | -$3 | -$4 | -$7 | -$6 |
| % Margin | -98.3% | -243.7% | -202.6% | -307.6% |
| EPS Diluted | -0.85 | -1.16 | -2.35 | -1.85 |
| % Growth | 26.7% | 50.6% | -27% | – |
| Operating Cash Flow | -$4 | -$2 | -$3 | -$8 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$4 | -$2 | -$3 | -$8 |